An Official Website of the United States Government
Company Information:
Name:
ADIPOGENIX, INC.
Address:
ADIPOGENIX, INC.
801 ALBANY ST, S112
BOSTON, MA 02119 0251
801 ALBANY ST, S112
BOSTON, MA 02119 0251
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
(617) 638-6389
Award Totals:
Award List:
ENHANCED DIFFERENTIATION OF HUMAN PREADIPOCYTES
Award Year / Program / Phase:
1999 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Geraldine Waloga
Award Amount:
$99,972.00
Abstract:
Not Available The objective of Phase I is to develop and demonstrate a neural networks system to predict, map, and interpolate rotorcraft ground noise exposure data. It is well-known that the relationships between ground noise exposures. Helicopter flight paths and operation conditions are… More
N/A
Award Year / Program / Phase:
2000 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Cydney C. Brooks
Award Amount:
$99,930.00
Anti-obesity drug development using human preadipocytes
Award Year / Program / Phase:
2001 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Geraldine Waloga
Award Amount:
$0.00
Anti-obesity drug development using human preadipocytes
Award Year / Program / Phase:
2001 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Geraldine Waloga
Award Amount:
$602,471.00
SECRETED PROTEIN FROM ADIPOCYTES AND PREADIPOCYTES
Award Year / Program / Phase:
2002 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Cydney C. Brooks
Award Amount:
$99,820.00
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. While weight loss is the most effective treatment of type 2 diabetes, current methods for reducing weight are typically insufficient for… More
New Agents That Inhibit Fatty Acid Accumulation
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Cydney C. Brooks
Award Amount:
$99,894.00
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Although weight loss is the most effective treatment for type 2 diabetes, current methods for reducing weight typically are insufficient for… More
Activators of Adipocyte Fatty Acid Oxidation
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Cydney C. Brooks
Award Amount:
$99,944.00
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing drug and dietary treatments for obesity are only modestly effective. An approach that is very likely to be effective in treating… More
New Agents That Inhibit Fatty Acid Accumulation
Award Year / Program / Phase:
2004 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Cydney C. Brooks
Award Amount:
$723,344.00
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing treatments for obesity are only modestly effective. The mission of AdipoGenix, Inc. is to discover and develop novel therapeutics… More